Haploidentical hematopoietic stem cell transplantation followed by post-transplant cyclophosphamide administration: A single-center retrospective study

Abstract

Human leukocyte antigen (HLA)-haploidentical hematopoietic stem cell transplantation followed by post-transplant cyclophosphamide (PTCy) administration for graft-versus-host disease (GVHD) prophylaxis is widely accepted worldwide. In this study, we retrospectively investigated the outcomes and safety of HLA-haploidentical hematopoietic stem cell transplantation followed by PTCy administration in 49 patients with hematological malignancy (median age 57 years). The 2-year overall survival, 2-year progression-free survival, 2-year GVHD/relapse-free survival, 1-year non-relapse mortality, 1-year acute GVHD grades 2–4, and 2-year chronic GVHD rates were 74.8%, 66.3%, 44.1%, 4.1%, 34.5%, and 40.5%, respectively. HLA-haploidentical hematopoietic stem cell transplantation followed by PTCy administration showed favorable outcomes and safety and can be recommended as a safe and effective transplantation option in Japan.